glucoplasmal 3,5% infúzió, 500 ml
b. braun melsungen ag - aminosavak -
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - daganatellenes szerek - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymphoma, mantle-cell - daganatellenes szerek - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).
sustac mite 2,6 mg retard tabletta
krka d.d., - gliceril trinitrate -
sustac forte 6,4 mg retard tabletta
krka d.d., - gliceril trinitrate -
paniverin tabletta
sanofi-aventis zrt. - a nikotinsav; drotaverine -
berotec n 100 mikrogramm/adag túlnyomásos inhalációs oldat
boehringer ingelheim international gmbh - fenoterol -
pädamin infúzió, 250 ml
fresenius kabi ag - aminosavak -
vamin 14 elektrolyte-free infúzió
fresenius kabi ag - aminosavak -
vamin 14 infúzió
fresenius kabi ag - aminosavak -